Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IXEKIZUMAB Cause Chronic kidney disease? 13 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Chronic kidney disease have been filed in association with IXEKIZUMAB (TALTZ). This represents 0.0% of all adverse event reports for IXEKIZUMAB.

13
Reports of Chronic kidney disease with IXEKIZUMAB
0.0%
of all IXEKIZUMAB reports
1
Deaths
5
Hospitalizations

How Dangerous Is Chronic kidney disease From IXEKIZUMAB?

Of the 13 reports, 1 (7.7%) resulted in death, 5 (38.5%) required hospitalization, and 2 (15.4%) were considered life-threatening.

Is Chronic kidney disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IXEKIZUMAB. However, 13 reports have been filed with the FAERS database.

What Other Side Effects Does IXEKIZUMAB Cause?

Injection site pain (3,799) Psoriasis (2,818) Drug ineffective (2,759) Injection site erythema (2,144) Injection site reaction (1,701) Injection site swelling (1,615) Incorrect dose administered (1,032) Covid-19 (861) Product dose omission issue (832) Therapy interrupted (796)

What Other Drugs Cause Chronic kidney disease?

OMEPRAZOLE (35,759) ESOMEPRAZOLE (35,281) LANSOPRAZOLE (32,517) PANTOPRAZOLE (28,127) DEXLANSOPRAZOLE (15,973) EMTRICITABINE\TENOFOVIR DISOPROXIL (10,248) TENOFOVIR DISOPROXIL (7,230) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (5,861) RABEPRAZOLE (4,773) ESOMEPRAZOLE\NAPROXEN (2,714)

Which IXEKIZUMAB Alternatives Have Lower Chronic kidney disease Risk?

IXEKIZUMAB vs JAKAFI IXEKIZUMAB vs JANUMET IXEKIZUMAB vs JANUVIA IXEKIZUMAB vs JETREA IXEKIZUMAB vs JUXTAPID

Related Pages

IXEKIZUMAB Full Profile All Chronic kidney disease Reports All Drugs Causing Chronic kidney disease IXEKIZUMAB Demographics